CytoMed Therapeutics Limited Ordinary Shares (GDTC) Live Share Price, Invest From India

CytoMed Therapeutics Limited Ordinary Shares Stock Performance

as on April 28, 2026 at 2:16 am IST

Day's High
$0.98
Day's Price Range
$1.00
$0.98
2.04%
Upside
52 Week's Low
52 Week's High
$0.73
52-Week Price Range
$3.68
$0.98
25.69%
Downside
275.51%
Upside

CytoMed Therapeutics Limited Ordinary Shares share price movements today

Previous Close: $0.95
Open: $1.00
Volume: 22.9K
Day's Low - High: $0.98 - $1.00
52 Week Low - High: $0.73 - $3.68

CytoMed Therapeutics Limited Ordinary Shares Historical Returns

1 Month Return: -7.7 %
3 Month Return: + 13.76 %
1 Year Return: -58.3 %
3 Year Return: 0 %
5 Year Return: 0 %

CytoMed Therapeutics Limited Ordinary Shares Stock Fundamentals & Key Indicators

Check CytoMed Therapeutics Limited Ordinary Shares market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$11.2M

EPS (TTM)

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-3.8M

Revenue (TTM)

860.8K

Profit Margin

0.00%

Return On Equity TTM

-50.28%

CytoMed Therapeutics Limited Ordinary Shares vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of CytoMed Therapeutics Limited Ordinary Shares with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
CytoMed Therapeutics Limited Ordinary Shares	BUY	$11.2M	NA	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$40.8B	116.23%	131.7	8.45%
Vertex Pharmaceuticals Inc	BUY	$109.5B	99.64%	28.1	32.94%
BeiGene, Ltd.	NA	$33.4B	NA	121.78	5.37%
Regeneron Pharmaceuticals Inc	BUY	$79.5B	52.82%	18.11	31.41%

Stock Returns calculator for CytoMed Therapeutics Limited Ordinary Shares Stock including INR - Dollar returns

The CytoMed Therapeutics Limited Ordinary Shares stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

CytoMed Therapeutics Limited Ordinary Shares investment value today

Current value as on today

₹47,539

Returns

-₹52,461

(-52.46%)

Returns from CytoMed Therapeutics Limited Ordinary Shares Stock

-₹57,018 (-57.02%)

Dollar Impact

₹4,556 (+4.56%)

Analyst Recommendation on CytoMed Therapeutics Limited Ordinary Shares Stock

Based on 7 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for CytoMed Therapeutics Limited Ordinary Shares. Average target price of $5

CytoMed Therapeutics Limited Ordinary Shares Share Price Target

Get share price movements and forecasts by analysts on CytoMed Therapeutics Limited Ordinary Shares.

What analysts predicted

80.4%UPSIDE

Target Price

Current Price

$0.98

Analyzed by

7 Analysts

Target

$5.00

CytoMed Therapeutics Limited Ordinary Shares target price $5, a slight upside of 80.4% compared to current price of $0.98. According to 7 analysts rating.

CytoMed Therapeutics Limited Ordinary Shares Stock’s Investor Sentiment and Interest

Search interest for CytoMed Therapeutics Limited Ordinary Shares Stock has decreased by -42% in the last 30 days, reflecting a downward trend in search activity.

Time period: March 28, 2026 to April 27, 2026

Change:-42% versus previous 30 day period

CytoMed Therapeutics Limited Ordinary Shares Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Dec 2025
Total Revenue	0	0	0	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0	0	0	0
Operating Income	0	-1	0	0	-1	0	0	0	-1
EBITDA	0	-1	0	0	0	0	0	0	-1
Interest Expense	0	0	-	0	0	-	0	0	0
Depreciation	-	-	-	-	-	-	-	-	-
Income Before Tax	0	-1	0	0	0	0	0	0	-1
Income Tax Expense	0	0	0	0	0	-	-	-	-
Net Income	0	-1	0	0	0	0	0	0	-1
Net Profit Margin	-759.30%	-1536.81%	-883.54%	-485.50%	-977.37%	-511.59%	-834.68%	-834.68%	-1030.69%

CytoMed Therapeutics Limited Ordinary Shares Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0
Operating Income	-1	-1	-1	-3	-2	-3
EBITDA	0	-1	-1	-2	-1	-3
Interest Expense	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0
Income Before Tax	-1	-1	-2	-3	-1	-3
Income Tax Expense	0	0	0	0	-	-
Net Income	-1	-1	-1	-2	-1	-3
Net Profit Margin	-3266.07%	-1822.31%	-839.94%	-1077.85%	-3621.15%	-1227.07%

CytoMed Therapeutics Limited Ordinary Shares Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Jun 2024	Sep 2024	Jun 2025	Dec 2025
Net Income	0	0	-1	0	0	0	-1
Operating Cash Flow	-1	0	-1	0	0	-1	-1
Investing Cash Flow	0	0	-	-1	1	0	0
Financing Cash Flow	8	0	0	0	0	0	0
Change in Cash	3	-3	0	-2	-	-1	0

CytoMed Therapeutics Limited Ordinary Shares Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-1	-1	-2	-3	-1	-3
Operating Cash Flow	0	-1	-1	-2	-1	-3
Investing Cash Flow	0	0	0	-2	0	0
Financing Cash Flow	1	3	0	8	0	0
Change in Cash	0	1	0	3	-1	-2

Insights on CytoMed Therapeutics Limited Ordinary Shares

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 100.04K → 130.62K (in $), with an average increase of 12.2% per quarter
NO EFFECT
Against Peers
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 24.7% return, outperforming this stock by 83.0%
NEGATIVE IMPACT
Price Dip
In the last 6 months, GDTC stock has moved down by -60.7%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 4 quarters, -555.67K → -1.34M (in $), with an average decrease of 36.2% per quarter

About CytoMed Therapeutics Limited Ordinary Shares

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

Organisation	CytoMed Therapeutics Limited Ordinary Shares
Headquarters	1 Commonwealth Lane, Singapore, Singapore, 149544
Industry	Biotechnology
CEO	Mr. Chee Kong Choo
E-voting on shares	Click here to vote

Key Management of CytoMed Therapeutics Limited Ordinary Shares

Name	Title
Mr. Chee Kong Choo	Executive Chairman
Dr. Jieming Zeng M.D., Ph.D.	Chief Scientific & Medical Officer and Director
Ms. Yvonne Goh	Chief Financial Officer
Dr. Tien Wee Luk M.D.	Chief Clinical Officer
Ms. Yoong Ying Tan	Chief Corporate Officer

FAQs

What is CytoMed Therapeutics Limited Ordinary Shares share price today?

CytoMed Therapeutics Limited Ordinary Shares share price today is $0.98 as on April 27, 2026 at 8:46 pm IST. CytoMed Therapeutics Limited Ordinary Shares share today touched a day high of $1 and a low of $0.98.

What is the 52 week high and 52 week low for CytoMed Therapeutics Limited Ordinary Shares share?

CytoMed Therapeutics Limited Ordinary Shares share touched a 52 week high of $3.68 on October 22, 2025 and a 52 week low of $0.73 on January 27, 2026. CytoMed Therapeutics Limited Ordinary Shares stock price today i.e. April 27, 2026 at 8:46 pm IST is trending at $0.98,which is 73.37% down from its 52 week high and 34.58% up from its 52 week low.

What is CytoMed Therapeutics Limited Ordinary Shares's market capitalisation today?

CytoMed Therapeutics Limited Ordinary Shares market capitalisation is $0.00T as on April 27, 2026 at 8:46 pm IST.

How to invest in CytoMed Therapeutics Limited Ordinary Shares Stock (GDTC) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for CytoMed Therapeutics Limited Ordinary Shares on INDmoney app. Click on Buy button. You can invest as low as $1.5 in CytoMed Therapeutics Limited Ordinary Shares Shares that will get you 1.5306 shares as per CytoMed Therapeutics Limited Ordinary Shares share price of $0.98 per share as on April 27, 2026 at 8:46 pm IST.

What is the minimum amount required to buy CytoMed Therapeutics Limited Ordinary Shares Stock (GDTC) from India?

Indian investors can start investing in CytoMed Therapeutics Limited Ordinary Shares (GDTC) shares with as little as ₹94.19 or $1 (as of April 27, 2026 at 9:43 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹941.90 in CytoMed Therapeutics Limited Ordinary Shares stock (as per the Rupee-Dollar exchange rate as on April 27, 2026 at 9:43 pm IST). Based on CytoMed Therapeutics Limited Ordinary Shares share’s latest price of $0.98 as on April 27, 2026 at 8:46 pm IST, you will get 10.2041 shares of CytoMed Therapeutics Limited Ordinary Shares. Learn more about fractional shares .